Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

4 treatments under study, led by Rituximab

Research Leaders

6 sponsors active, led by Brigham and Women's Hospital

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

50% success

Data Visualizations

Phase Distribution

2Total
Phase 1/2 (1)
Phase 2 (1)

Trial Status

Terminated1
Completed1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00596804Phase 1/2Completed

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

NCT00455897Phase 2Terminated

CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

Showing all 2 trials

Research Network

Common Treatments

  • Rituximab1
  • Chop1
  • Veltuzumab1
  • Granulocytemacrophage Colonystimulating Factor1

Active Sponsors

  • Brigham and Women's Hospital1
  • Bayer1
  • Beth Israel Deaconess Medical Center1
  • Dana-Farber Cancer Institute1
  • Gilead Sciences1

Top Investigators

Related Conditions

  • Nonhodgkins Lymphoma1
  • Lymphoma Bcell1
  • Lymphoma Diffuse Mixed Lymphocytichistiocytic1
  • Lymphoma Nonhodgkin1

Activity Timeline